Lebrikizumab for Atopic Dermatitis

(ADfind Trial)

Recruiting at 3 trial locations

Overseen By Diane Fiolek

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Johann E Gudjonsson MD PhD

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

Research Team

Johann E. Gudjonsson, MD, PhD

Principal Investigator

University of Michigan

Eligibility Criteria

This trial is for individuals with moderate-to-severe atopic dermatitis, including eczema of the ear canal and vasculopathic skin disease. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be excluded based on factors that could impact their safety or the study's results.

Inclusion Criteria

Subject willing and able to comply with all of the clinical study protocol's time commitments and procedural requirements

Understand and sign an informed consent form (ICF) before any investigational procedure(s) are performed

I have had AD for over a year and topical treatments haven't worked or aren't suitable.

Exclusion Criteria

Severe concomitant illness(es) that may adversely affect participation in the study

Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

History of human immunodeficiency virus (HIV) infection

Treatment Details

Interventions

• Lebrikizumab (Monoclonal Antibodies)

Trial Overview The study is examining lebrikizumab, a drug approved for treating atopic dermatitis. It aims to collect health data along with blood and skin samples from participants to evaluate long-term improvements in AD symptoms.

Participant Groups

Group I: Moderate-to-severe Atopic Dermatitis Experimental Treatment 1 Intervention

A total of 48 subjects with active moderate-to-severe Atopic Dermatitis (AD) will be enrolled in a 60-week study from 4 independent sites (2 US sites and 2 EU sites).

Who Is Running the Clinical Trial?

Johann E Gudjonsson MD PhD

Lead Sponsor

Almirall, S.A.

Industry Sponsor

Trials

63

Recruited

19,200+

Carlos Gallardo Piqué

Almirall, S.A.

Chief Executive Officer since 2023

MS in Industrial Engineering from Universitat Politècnica de Catalunya, MBA from Stanford Graduate School of Business

Mercedes Diz

Almirall, S.A.

Chief Medical Officer since 2023

PhD in Biochemistry

Dermira, Inc.

Industry Sponsor

Trials

17

Recruited

6,100+